Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future

Coordination of COVID-19 Vaccine Clinical Trials Produces a ‘Treasure Trove’ of Data and a Model for the Future

Harmonized approach and vast database of trial participants could bolster future research well beyond SARS-CoV-2
News ReleasesJanuary 23, 2023
Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review

Phase 3 Mosaic-Based Investigational HIV Vaccine Study Discontinued Following Disappointing Results of Planned Data Review

HVTN researchers and ethicists say findings will help guide new approaches to HIV vaccine studies
News ReleasesJanuary 18, 2023
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
News ReleasesAugust 24, 2022
HVTN at the 24th International AIDS Conference in Montreal

HVTN at the 24th International AIDS Conference in Montreal

HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more
News ReleasesJuly 28, 2022
CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

Response comparable to mRNA vaccines and if authorized, could help bolster global vaccine supplies
News ReleasesJune 28, 2022
Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine

Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
News ReleasesMarch 17, 2021